Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC raised its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 28.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,264 shares of the company’s stock after purchasing an additional 2,264 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Elanco Animal Health were worth $124,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. Commerce Bank boosted its position in Elanco Animal Health by 2.2% during the 3rd quarter. Commerce Bank now owns 35,114 shares of the company’s stock valued at $516,000 after purchasing an additional 741 shares during the period. MTM Investment Management LLC raised its position in Elanco Animal Health by 9.3% during the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company’s stock valued at $172,000 after buying an additional 1,200 shares during the period. M&T Bank Corp increased its stake in shares of Elanco Animal Health by 5.9% in the third quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock worth $388,000 after acquiring an additional 1,464 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in Elanco Animal Health by 1.4% in the third quarter. Parkman Healthcare Partners LLC now owns 127,812 shares of the company’s stock worth $1,878,000 after buying an additional 1,770 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock worth $71,000 after purchasing an additional 1,894 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Friday, March 7th. The stock was bought at an average price of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the transaction, the director now owns 101,459 shares in the company, valued at $1,105,903.10. This represents a 10.93 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Elanco Animal Health Trading Up 1.5 %

ELAN opened at $10.47 on Monday. The company’s 50 day moving average is $11.46 and its 200-day moving average is $12.73. The company has a market cap of $5.18 billion, a P/E ratio of 26.16, a PEG ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 1-year low of $10.03 and a 1-year high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business earned $0.08 earnings per share. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ELAN shares. Morgan Stanley lowered their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. UBS Group cut their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Piper Sandler cut their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Barclays dropped their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Finally, Leerink Partners assumed coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.